Description
Maximus, Inc.: Strategic Portfolio Realignment for Global Expansion Driving Our ‘Buy’ Rating!
Maximus recently reported its fiscal year 2024 earnings, illustrating a robust financial performance underpinned by strategic advancements and significant contracts, albeit amid some challenges and uncertainties. For the year, Maximus achieved 8.2% growth in consolidated revenue, amounting to $5.31 billion, with organic growth at 8.8%. This was driven by increased volumes in core programs and Medicaid-related activities, reflecting the resumption to pre-pandemic levels and additional volumes managed throughout the year.
Our Report Structure:
⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures
Want unlimited access to our reports? Purchase our $99 annual subscription!